About

At Chugai Pharmabody Research (CPR) our drug discovery efforts are driven by our mission to advance patient-centric healthcare. As a core research institute of Chugai Pharmaceutical, a member of the Roche Group, we are committed to developing innovative drugs that can unlock new therapeutic possibilities for patients with unmet medical needs.

Over the past decade, we have leveraged our proprietary antibody engineering and cyclic peptide technologies to develop promising drug candidates. This includes breakthrough antibody therapy treatment for paroxysmal nocturnal hemoglobinuria, which has achieved regulatory approval in Japan, Europe, and the US. This milestone reinforces CPR’s position as a global leader in drug discovery.

Our success is deeply rooted in Singapore’s vibrant science ecosystem. We have thrived thanks to Singapore’s robust research infrastructure, access to a diverse pool of highly trained multinational scientists, and supportive policies that advance biomedical research.

Looking ahead, we remain focused on developing groundbreaking medicines that can transform patient care. We will continue to nurture a workplace where our people can amplify their impact through their research.

Building strong, trusted research partnerships remains a priority. Our joint research with the Agency for Science, Technology and Research (A*STAR) on the development of anti-dengue virus and COVID-19 antibodies reflect how such collaborations can transform unique research into tangible therapies.

By deepening collaborations, we aim to advance innovative therapies and support the ongoing growth of Singapore’s science ecosystem for shared, sustainable success.